 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Disc Medicine Opco Inc. (IRON) operates as a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. 
The company builds a portfolio of fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. It also develops bitopertin for the treatment of erythropoietic porphyrias, erythropoietic protoporphyria, and X-linked protoporphyria.
In addition, the company develops DISC-0974 for the treatment of chronic kidney disease; MWTX-003 for the treatment of polycythemia vera, and other hematologic disorders; and DISC-0998 for the treatment of anemia associated with inflammatory.
Shares have formed a bullish "cup and handle" and higher share prices are expected. Higher share prices are expected. On August 11th, IRON reported a loss of $0.74 per share for the second quarter ended June 2023. The consensus estimate was a loss of $0.88 per share. The company beat consensus estimates by 15.91%.
Entry Point: $54.50
Stop Loss: $52.00
Trading Range: $11.80 to $57.70
Target Price: $60.00
